Wednesday, 18 February 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 18 February 2026
News

Aussies cashed up for US spin-off

Posted 17 February 2026 PM

Ternarx has secured “significant investment” to create a US-based spin-off company, Ternarx Bio, to advance its lead program in prostate cancer.

It marks less than two years since Health Minister, Mark Butler, announced the official launch of Ternarx, a WEHI spin-out company borne from the Australian Centre for Targeted Therapeutics (ACTT) in Bundoora, which received a $15 million grant from the Australian government’s Medical Research Future Fund (MRFF) Frontier Health and Medical Research initiative in October 2023.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (4)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.